Perioperative landiolol hydrochloride for preventing of atrial fibrillation after lung resection

Perioperative landiolol hydrochloride for preventing of atrial fibrillation after lung resection - Perioperative landiolol hydrochloride for preventing of atrial fibrillation after lung resection

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007561

Enrollment

100

Registered

2012-04-01

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Intravenous prasebo, Glucose 5% during operation. Intravenous landiolol hydrochloride during the operation.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients who have lung cancer, to be treated by pnemonectomy or bilbectomy.

Exclusion criteria

Exclusion criteria: (1) patients without previous or current cardiovascular history (2) bradycardia (3) superventricular arrhythmia (4) significant alteration of atrioventricular conduction Patients with sick sinus syndromr Patients with chronic inflammatory disease Patients with moderate - severe valvular disease Patients with significant liver failure Patients with significant renal failure

Design outcomes

Primary

Measure	Time frame
the frequency of atrial fibrillation	—

Countries

Japan

Contacts

Public ContactYagi Kaori

Nippon Medical School Department of Anesthesiolgy

fuku-kaori@nms.ac.jp0338222131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026